Background: The receptor of ciliary neurotrophic factor (CNTF) contains the signal transduction protein gpI30, which is also a component of the receptors of cytokines such as interleukin (IL)-6, leukemia-inhibitory factor (LIF), IL-lI, and oncostatin M. This suggests that these cytokines might share common signaling pathways. We previously reported that CNTF augments the levels of corticosterone (CS) and of IL-6 induced by IL-1 and induces the production of the acute-phase protein serum amyloid A (SAA). Since the elevation of serum CS is an important feedback mechanism to limit the synthesis of proinflammatory cytokines, particularly tumor necrosis factor (TNF), we have investigated the effect of CNTF on both TNF production and lipopolysaccharide (LPS) 
INTRODUCTION
Proinflammatory cytokines, particularly tumor necrosis factor (TNF) and interleukin (IL)-1, play important roles in infectious, inflammatory and autoimmune diseases. In particular, TNF appears to mediate the toxicity induced by lipopolysaccharide (LPS) and to act in some diseases of the central nervous system, such as allergic encephalomyelitis, bacterial meningitis, and cerebral malaria (1) .
The pathogenic effects of proinflammatory cytokines result from their action on several cellular targets, some of which, in turn, cause the triggering of "anti-inflammatory" feed-back responses. These include the induction of hepatic acute-phase proteins (such as proteinase inhibitors and antioxidants), and the activation of the hypothalamus-pituitary-adrenal axis (HPAA), which ultimately increases serum levels of corticosterone (CS), a potent inhibitor of cytokine synthesis (2) .
Induction of at least some acute-phase proteins by either IL-1 or TNF is mediated by (3). IL-6 also synergizes with IL-I to activate the HPAA (4) , and thus appears to play a central role in mediating anti-inflammatory responses. It should be noted that, while administration of TNF or IL-I induces LPS shock-like symptoms and toxicity, administration of does not induce toxicity but only some metabolic changes associated with the acute-phase response, namely, APP synthesis and fever (5) . This absence of toxicity further illustrates the anti-inflammatory role of It was recently established that the gpl30 subunit of the receptor is an accessory component of the receptors of many other cytokines, such as leukemia inhibitory factor (LIF), IL-Il, oncostatin M, ciliary neurotrophic factor (CNTF), and cardiotrophin-1 (6, 7) . Interestingly, some of these "gpl 30-user cytokines" have common pharmacological properties, including a protective action in animal models of inflammation. LIF protects against endotoxic shock (8, 9) and pulmonary inflammation induced by intratracheal injection of LPS (10); IL-6 suppresses de-myelination in a viral model of multiple sclerosis (11) and inhibits TNF production both in vivo and in vitro (9, 12) . All gpl30-user cytokines tested (LIF, IL-6, oncostatin M, and CNTF) act as hepatocyte-stimulating factors, directly stimulating APP synthesis (13) (14) (15) . Finally, both CNTF and IL-6 enhance the activation of the HPAA by IL-I (15), which might further contribute to the protective action of gpl30-user cytokines.
Because it targets primarily neuronal cells, CNTF was not expected to have a wide range of activities compared with the other gpl30-user cytokines. In vitro experiments have however shown that CNTF, in combination with its soluble receptor sCNTFRa, inhibits the synthesis of proinflammatory cytokines in human peripheral blood mononuclear cells and human fibroblasts (16) . This suggests that circulating sCNTFRa may render a wide range of non-neuronal cells responsive to CNTF. This is supported by the observation that recombinant sCNTFRa confers functional responsiveness to CNTF to cells that do not express the a subunit of the receptor complex on their surface, with the same relative affinity and specificity of the cell-surface form (17, 18) .
In order to evaluate the physiopathological relevance of these actions of CNTF, we have characterized the effects of administering CNTF (either alone or in combination with sCNTFRa) in an animal model of LPS toxicity. We also studied the effect of CNTF on TNF production in vivo, by measuring serum TNF levels after i.p. administration of LPS, and in vitro in mouse splenocytes, and its ability to act in synergy with the synthetic glucocorticoid dexamethasone (DEX).
Since CNTF is a neurotrophic factor, we also studied its effect on TNF production in the brain. For this purpose, mice were injected with LPS intracerebroventricularly (i.c.v.), as peripheral injection of LPS does not produce detectable levels of TNF in the brain (19) .
MATERIALS AND METHODS

Materials
Recombinant human CNTF, purified from Escherichia coli, was obtained from Regeneron Pharmaceuticals Inc. (Tarrytown, NY, U.S.A.). EC50 of CNTF in the E8 chicken ciliary ganglion neuronal survival assay was 0.24 ng/ml (20) . Recombinant human soluble CNTF receptor a (sCNTFRa) was prepared from E. coli as previously described (18 Splenocyte Cultures BALB/c mice were sacrificed and spleens were removed and disaggregated by washing with RPMI 1640 medium using a 2.5-ml syringe. Splenocytes were counted and plated at 10 x 106/ml in 96-well culture plates (100 ,ul/well). Cells were cultured in RPMI 1640 medium with 10% FCS in the presence of 1 ,ug/ml LPS, with and without CNTF, sCNTFRa, or DEX, at the indicated concentrations in a final volume of 200 ,ul/well. Four hours later, supernatants were harvested and assayed for TNF levels.
The IC50 values for DEX were established by simultaneous nonlinear curve fitting according to the logistic equation reported by De Lean et al. (23) , using the "Allfit" program.
Miscellaneous Assays TNF activity was measured by cytotoxicity on L929 cells as previously described (24) (Fig. 3) .
Effect of CNTF on LPS-Induced CS and SAA As shown in Table 1 , CNTF administered simultaneously with LPS slightly but significantly increased the peak levels of serum CS. CNTF alone had no effect serum CS levels. As previously reported (15) , CNTF alone induced a significant elevation of serum SAA levels ( LPS + CNTF + sCNTFRa. TNF production in the absence of DEX was: 1570 ± 479 for LPS alone; 1007 ± 308 pg/ml (mean SD; n = 3) for LPS with CNTF. not shown). However, the effect was not statistically significant. In other experiments, CNTF was tested at various concentrations (from 0.2 to 20 ,ug/ml) without any significant effect on TNF production. Addition of sCNTFRa (20 ,g/ml) did not increase the effect of CNTF (data not shown).
CNTF, however, augmented the inhibitory effect of DEX, shifting its IC50 from 5.8 X 10-8 (±1.4 X 10-8) to 2.1 X 10 9 (±1.3 X 10 9) M (Fig. 4) . The difference between the two IC50 was statistically significant (p < 0.05 using the Allfit program). Once again, exogenously added sCNTFRa (20 jig/ml) did not enhance this effect of CNTF.
DISCUSSION
The present report shows that CNTF is an inhibitor of LPS-induced serum TNF levels and protects against LPS toxicity when combined with its soluble receptor. In our previous work, CNTF was shown to increase the levels of serum CS, SAA, and IL-6, induced by IL-1 (1 5). Production of endogenous corticosteroids represents an important feedback mechanism against proinflammatory cytokines, as demonstrated by the observation that adrenalectomy sensitizes mice to the lethal effect of LPS, TNF, and IL-1 (27) , and increases TNF production in vivo (28) . The activation of the HPAA response by CNTF might therefore have a role in the observed inhibition of TNF production.
A similar protective role has been demonstrated for at least some acute-phase proteins. Mice treated with a-acid glycoprotein are protected against TNF-induced lethality (29) , and transgenic mice expressing rabbit C-reactive protein are protected from complement-mediated lung injury (30) . SAA was also reported to inhibit IL-I-and TNF-induced fever and PGE2 production (3 1). It is possible that these mechanisms are involved both in the protective effect of CNTF reported in this study, and in the anti-LPS actions of LIF and IL-6 previously reported (8) (9) (10) 12) .
CNTF was, however, found to have only a minor effect on the levels of serum CS induced by LPS and no effect on SAA levels, most likely because LPS induces maximal levels of these proteins. It is therefore unlikely that the inhibition of TNF production and of LPS toxicity by CNTF is due only to the activation of feedback regulatory mechanisms, but suggests that other, direct effects of CNTF are involved.
The data obtained in vitro, using cultured mouse spleen cells, indicate that CNTF, even at high concentrations, only slightly inhibits TNF production. Once again this can hardly explain the marked inhibition of serum (and brain) TNF levels observed in LPS-treated mice. On the other hand, the finding that CNTF enhances the inhibitory effect of a glucocorticoid, dexamethasone, decreasing its IC50 by about 25-fold, suggests that CNTF not only affects the activation of the HPAA but also the inhibitory effect of glucocorticoids on TNF production. Inhibition of TNF production may therefore result from a combination of effects of CNTF: (1) direct inhibition of TNF production; (2) activation of the HPAA; and (3) increasing the inhibition of TNF production by glucocorticoids.
As far as the protective effect on LPS toxicity is concerned, inhibition of serum TNF levels does not entirely account for the protective action of CNTF. The inhibition of TNF production (both at peak levels and at 3 hr) did not differ whether CNTF was administered alone or together with sCNTFRa; similarly, serum CS and SAA were not significantly elevated when sCNTFRa was added. sCNTFRa, however, significantly enhanced the protection against a lethal dose of LPS. In addition, it should be noted that, for this experimental model, CNTF (with or without its soluble receptor) was not able to completely block TNF production, raising the possibility that CNTF acts both on TNF production and on its toxicity.
The requirement for sCNTFRa to gain a maximal protective effect might be explained by the following hypotheses: (1) injection of soluble receptors might confer responsiveness to cells that normally do not respond to CNTF because they display gp130 and LIF receptors, but not the specific receptor subunit; or (2) the soluble receptor might change the pharmaco-kinetics and tissue distribution of CNTF, as soluble cytokine receptors have been shown to prolong the pharmaco-kinetic half-life of recombinant cytokines. Further studies are necessary to investigate these possibilities.
In conclusion, our data are consistent with the idea that cytokines like CNTF, LIF, or IL-6 (gp130-users) have an anti-inflammatory action rather than a pathogenetic role in septic shock. It is noteworthy that the only report of protection against LPS toxicity by anti-IL-6 antibodies was associated with increased, rather than inhibited, serum IL-6 levels (32), probably due to a "chaperone" effect of the antibody. In fact, IL-6 knockout mice have higher serum TNF levels after LPS injection than normal mice (33) , supporting the hypothesis that IL-6 inhibits TNF production.
The present study has also shown that CNTF inhibits TNF production in the central nervous system. This observation might be important to TNF-mediated pathologies of the central nervous system; in particular, in experimental allergic encephalomyelitis susceptibility to the disease is related to endogenous corticosteroids levels and to the efficiency of the HPAA feedback response (34, 35) .
It was recently reported that TNF induces cell death in oligodendrocytes and that this effect can be prevented by CNTF (36) . It is therefore possible that, under certain conditions, CNTF might counterbalance the effects of TNF. Further studies involving measurements of CNTF levels after LPS treatment or neutralization of CNTF with antibodies, will be required to determine whether CNTF represents yet another feedback regulator of TNF production.
